ENDONOVO THERAPEUTICS, INC. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)
ENDONOVO THERAPEUTICS, INC. (ENDV) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) of -$5.61 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-04-13.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease · last filed 2021-04-13
- ENDONOVO THERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for fiscal 2020 was -$5.61M, a 174.88% decline from fiscal 2019.
- ENDONOVO THERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for fiscal 2019 was $7.49M.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 12 month |
|---|---|
| 2020-12-31 | -$5.61M 10-K · filed 2021-04-13 |
| 2019-12-31 | $7.49M 10-K · filed 2021-04-13 |